<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002054</url>
  </required_header>
  <id_info>
    <org_study_id>022C</org_study_id>
    <secondary_id>87-71 (Part C)</secondary_id>
    <nct_id>NCT00002054</nct_id>
  </id_info>
  <brief_title>A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</brief_title>
  <official_title>A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisons</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and description of time to Pneumocystis carinii&#xD;
      pneumonia (PCP) for long-term biweekly administration of 1 of 2 doses of aerosol pentamidine&#xD;
      when used as a prophylactic agent in patients who have had one episode of AIDS-associated&#xD;
      PCP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine isethionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients who have completed 16 treatments under Fisons study no. 87-71 entitled, &quot;A&#xD;
        Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three&#xD;
        Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia&#xD;
        in Patients With AIDS Post First Episode PCP.&quot; Detailed safety parameters must have been&#xD;
        documented for 6 months.&#xD;
&#xD;
          -  Patients must receive the first dose on this study within 2 weeks of their last dose&#xD;
             under study no. 87-71.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of&#xD;
             entry or those patients with either of the following AIDS-defining O.I.'s at entry:&#xD;
&#xD;
          -  Toxoplasmosis.&#xD;
&#xD;
          -  Cryptococcosis.&#xD;
&#xD;
          -  Pulmonary Kaposi's sarcoma.&#xD;
&#xD;
          -  Asthma poorly controlled by medication.&#xD;
&#xD;
          -  Receiving active therapy for tuberculosis.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of&#xD;
             entry or those patients with either of the following AIDS-defining O.I.'s at entry:&#xD;
&#xD;
          -  Toxoplasmosis.&#xD;
&#xD;
          -  Cryptococcosis.&#xD;
&#xD;
          -  Pulmonary Kaposi's sarcoma.&#xD;
&#xD;
          -  Unwilling to sign informed consent.&#xD;
&#xD;
          -  Cannot cooperate with study procedures.&#xD;
&#xD;
          -  Asthma poorly controlled by medication.&#xD;
&#xD;
          -  Receiving active therapy for tuberculosis.&#xD;
&#xD;
        Active substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fisons Corp</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hogan CH, Hodges JS, Mugglin A, Peterson PM, Abrams DI, Saravolatz L. The perils of visit-driven endpoints in antiretroviral trials. Int Conf AIDS. 1996 Jul 7-12;11(1):237 (abstract no TuB522)</citation>
  </reference>
  <reference>
    <citation>Wulfsohn M, Fischl M, Tsiatis A. Predictors of survival among patients with AIDS receiving zidovudine. Int Conf AIDS. 1992 Jul 19-24;8(2):C314 (abstract no PoC 4419)</citation>
  </reference>
  <reference>
    <citation>De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr (1988). 1993 Apr;6(4):359-65.</citation>
    <PMID>8095980</PMID>
  </reference>
  <reference>
    <citation>Lavelle J, Murphy R, Harding P, Pierce P. Aerosolized pentamidine prophylaxis following Pneumocystis carinii pneumonia in patients with AIDS. Int Conf AIDS. 1990 Jun 20-23;6(2):374 (abstract no 2083)</citation>
  </reference>
  <verification_date>October 1989</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

